科研之友
微信
新浪微博
Facebook
分享链接
摘要
This article focuses on new antithrombotic drugs that are in or are entering phase 3 clinical testing. Development of these new agents was prompted by the limitations of existing antiplatelet, anticoagulant, or fi brinolytic drugs. Addressing these unmet needs, this article (1) outlines the rationale for development of new antithrombotic agents; (2) describes the new antiplatelet, anticoagulant, and fi brinolytic drugs; and (3) provides clinical perspectives on the opportunities and challenges faced by these novel agents.
- 出版日期2012-2
